Tavira Therapeutics

Leuven ·KBO/BCE: BE 0802.591.262

Loading dossier…

Metric	This company	Sector median	Position in the sector
Solvency	22.0%	55.0%	better than 28% of 174 sector peers
Net result	€-921k	€16k	better than 5% of 174 sector peers
Equity	€245k	€70k	better than 83% of 174 sector peers
Gross operating margin	€-122k	€41k	better than 5% of 175 sector peers
Staff costs	€21k	€58k	higher than 36% of 38 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€1.11M
Fixed assets	21/28	€679k
Intangible fixed assets	21	€678k
Tangible fixed assets	22/27	€991
Current assets	29/58	€434k
Amounts receivable within one year	40/41	€48k
Cash & bank	54/58	€326k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€1.11M
Equity	10/15	€245k
Contributions / capital	10/11	€1.17M
Accumulated profits (losses)	14	€-921k
Amounts payable	17/49	€868k
Amounts payable after one year	17	€785k
Amounts payable within one year	42/48	€84k
Trade debts payable within one year	44	€80k
Income statement
Gross operating margin	9900	€-122k
Operating result	9901	€-941k
Financial income	75	€220
Financial charges	65	€37k
Result before taxes	9903	€-978k
Income taxes	67/77	€-57k
Net result for the period	9904	€-921k
Result to be appropriated	9905	€-921k

NACE primary	Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied(72109)
Legal form	Private limited company(610)
Incorporation	09-06-2023
Status	Active
Postal code	3001

Summary

Parcel (capakey)	Region	Area	Buildings	Height / fl.
24040B0201/00H002	Flanders	7,000 m²	1 · 1,139 m²	17.0 m · 4 fl.
24040B0218/00V002	Flanders	2,297 m²	1 · 1,484 m²	2.6 m